ROS signaling in systemic and cellular responses to chronic intermittent hypoxia
ROS signaling in systemic and cellular responses to chronic intermittent hypoxia
复制标题
DOI：
10.1089/ars.2007.1732
复制
发表时间：
2007-09-01
影响因子：
6.6
通讯作者：
Semenza, Gregg L.
中科院分区：
文献类型：
--
作者：
Prabhakar, Nanduri R.;Kumar, Ganesh K.;Semenza, Gregg L.
慢性间歇性缺氧（CIH）是一种常见的危及生命的疾病，发生在许多不同的疾病中，包括表现为复发性呼吸暂停的睡眠呼吸障碍。活性氧（ROS）是多种疾病的致病因素之一。本文的目的是提出一个简短的概述，最近的研究涉及的关键作用，在引起表型的不良反应CIH的实验模型和复发性呼吸暂停患者的ROS。在实验模型中，CIH激活ROS信号传导，其有助于几种全身和细胞反应，包括（a）改变的颈动脉体功能，其是用于感测动脉血O-2变化的主要化学感受器;（B）升高的血压;（c）增强的递质和神经营养因子的释放;（d）改变的睡眠和认知行为;（e）增加的神经营养因子;（f）增加的神经营养因子;（g）增加的神经和（e）激活第二信使途径和转录因子。相当多的证据表明，在CIH患者中，ROS水平升高是复发性呼吸暂停的结果。抗氧化剂不仅可以防止许多CIH诱发的生理和细胞反应在实验环境中，但更重要的是，他们也提供了某些表型的不良反应，在复发性呼吸暂停患者的保护，这表明其潜在的治疗价值，在减轻某些疾病与复发性呼吸暂停。
Chronic intermittent hypoxia (CIH) is a common and life-threatening condition that occurs in many different diseases, including sleep-disordered breathing manifested as recurrent apneas. Reactive oxygen species (ROS) have been identified as one of the causative factors in a variety of morbidities. The purpose of this article is to present a brief overview of recent studies implicating a critical role of ROS in evoking phenotypic adverse effects in experimental models of CIH and in patients with recurrent apneas. In experimental models, CIH activates ROS signaling that contributes to several systemic and cellular responses that include ( a) altered carotid body function, the primary chemoreceptor for sensing changes in arterial blood O-2; (b) elevated blood pressures; ( c) enhanced release of transmitters and neurotrophic factors; (d) altered sleep and cognitive behaviors; and ( e) activation of second-messenger pathways and transcriptional factors. Considerable evidence indicates elevated ROS levels in patients experiencing CIH as a consequence of recurrent apneas. Antioxidants not only prevent many of the CIH-evoked physiologic and cellular responses in experimental settings, but more important, they also offer protection against certain phenotypic adverse effects in patients with recurrent apneas, suggesting their potential therapeutic value in alleviating certain morbidities associated with recurrent apneas.